- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Duvelisib Produces Responses in Indolent Non-Hodgkin Lymphoma
December 16th 2014, 7:31am
ASH Annual Meeting and Exposition
Duvelisib (IPI-145), an inhibitor of PI3K-δ and PI3K-γ signaling, had a favorable risk:benefit profile in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) in a phase I study, reported Ian Flinn, MD, PhD
Tyrosine Kinase Inhibitor Shows Promise in AML
December 15th 2014, 4:08pm
ASH Annual Meeting and Exposition
Treatment with the TKI sorafenib in combination with standard chemotherapy increased event-free survival by 11.3 months compared with standard chemotherapy plus placebo in patients with newly diagnosed acute myeloid leukemia.
Gene Test Predicts DCIS Recurrence Risk
December 12th 2014, 3:52pm
San Antonio Breast Cancer Symposium
A 12-gene test for breast cancer recurrence after ductal carcinoma in situ (DCIS) distinguished high- and intermediate- risk patients from those with a low risk
Women With Triple-Negative Breast Cancer May Reap Greater Survival Benefit From Nutrition Intervention
December 12th 2014, 2:34pm
San Antonio Breast Cancer Symposium
Findings from a long-term analysis of the Women's Intervention Nutrition Study (WINS) show that the deaths of women with hormone receptor–negative breast cancers were reduced by up to 54% when they followed a program to reduce their dietary fat intake, which could provide benefit for patients with triple-negative breast cancer.
HR-Negative Subgroup Data Offer Silver Lining to Everolimus Frontline Failure in BOLERO-1
December 12th 2014, 2:24pm
San Antonio Breast Cancer Symposium
Frontline treatment with everolimus (Afinitor) combined with trastuzumab (Herceptin) and paclitaxel failed to delay disease progression versus trastuzumab and paclitaxel alone in patients with HER2-positive advanced breast cancer
Upfront Fulvestrant Improves Survival Over Anastrozole in HR-Positive MBC
December 12th 2014, 1:19pm
San Antonio Breast Cancer Symposium
Fulvestrant (Faslodex) improved overall survival (OS) by 5.7 months compared with anastrozole as a frontline treatment for postmenopausal women with HR-positive metastatic breast cancer
Dr. Nanda On Pembrolizumab Potential for TNBC
December 12th 2014, 12:47pm
San Antonio Breast Cancer Symposium
Rita Nanda, MD, assistant professor of medicine and associate director of the Breast Medical Oncology Program at the University of Chicago, discusses the potential of pembrolizumab (Keytruda) for the treatment of triple-negative breast cancer (TNBC). A recent small-scale trial showed treatment response for 18.5% of patients with PD-L1 positive TNBC.
Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC Subtype
December 12th 2014, 10:36am
Dr. Cuzick on Decreasing Breast Cancer Risk With Tamoxifen
December 11th 2014, 4:18pm
Chemo Adds No Benefit to Bisphosphonate In Older Breast Cancer Patients
December 11th 2014, 3:42pm
San Antonio Breast Cancer Symposium
Older patients with moderate- or high-risk breast cancer had a similar disease-free survival with the bisphosphonate therapy ibandronate alone or in combination with capecitabine.
Tamoxifen's Sustained Power to Prevent Breast Cancer in High-Risk Women Confirmed
December 11th 2014, 3:36pm
San Antonio Breast Cancer Symposium
Five years of tamoxifen continues to offer protection against breast cancer, reducing the risk of breast cancer by 29% in otherwise healthy women at high risk of the disease who have been followed now for 16 to 22 years.
Ovarian Suppression Emerges as "Practice-Changing" Option for Younger, Premenopausal Breast Cancer Patients
December 11th 2014, 2:41pm
San Antonio Breast Cancer Symposium
Women with HR+ breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant exemestane or-to a lesser extent-tamoxifen, compared with standard tamoxifen alone, according to results from the phase III SOFT trial.
TNBC Subtype Responds Favorably to Neoadjuvant Bevacizumab
December 11th 2014, 2:29pm
San Antonio Breast Cancer Symposium
The addition of bevacizumab (Avastin) to standard neoadjuvant chemotherapy significantly improved pathologic complete response (pCR) rates in women with basal-like breast cancer compared with non-basal-like subtypes.
Dr. Francis on the Benefits of Ovarian Suppression for Younger Women
December 11th 2014, 12:30pm
Nab-Paclitaxel Wins Neoadjuvant Taxane Battle in Breast Cancer Trial
December 11th 2014, 8:33am
San Antonio Breast Cancer Symposium
Nab-paclitaxel (Abraxane) proved markedly more effective than conventional paclitaxel as part of a neoadjuvant regimen for patients with high-risk early breast cancer in a large German study presented at the 2014 San Antonio Breast Cancer Symposium.
Dr. Weigert on Cancer Screening for Women With Dense Breasts
December 10th 2014, 3:33pm
Dr. Edith Perez on Immune Checkpoint Inhibition in TNBC
December 10th 2014, 3:24pm
San Antonio Breast Cancer Symposium
Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the potential for immune checkpoint blockage as treatment for patients with advanced breast cancer.
Pembrolizumab Elicits Antitumor Responses in TNBC
December 10th 2014, 12:54pm
San Antonio Breast Cancer Symposium
The PD-1 inhibitor pembrolizumab has demonstrated promising clinical activity with an acceptable safety profile in heavily pretreated patients with recurrent metastatic triple-negative breast cancer.
Early Data Find the PI3K Inhibitor Pictilisib Benefits a Subset of Patients With MBC
December 10th 2014, 12:45pm
San Antonio Breast Cancer Symposium
The addition of the investigational PI3K inhibitor pictilisib to fulvestrant in patients with metastatic breast cancer yielded some intriguing findings in the phase II FERGI study.
Chemo Alone May Be Optimal in HER2-Positive Patients With High TIL Levels
December 10th 2014, 12:11pm
San Antonio Breast Cancer Symposium
Among HER2-positive breast cancer patients treated with chemotherapy alone, women with high levels of stromal tumor-infiltrating lymphocytes had an 80% lower likelihood of disease recurrence compared to those with lower TIL counts.